Loading
Hagop Kantarjian is one of the most prolific leukaemia investigators alive, and helped bring more than a dozen leukaemia drugs to approval.
Hagop Kantarjian is Chair of the Department of Leukemia at MD Anderson Cancer Center, a post he has held since 1999. A leukaemia specialist in CML, ALL and drug development, he is one of the most prolific leukaemia investigators alive and led pivotal trials in CML with imatinib, dasatinib and ponatinib, in ALL with inotuzumab and blinatumomab combinations, and in AML. His papers include the New England Journal of Medicine reports of inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukaemia, from the INO-VATE ALL trial, and of blinatumomab versus chemotherapy for advanced acute lymphoblastic leukaemia. He is also a vocal advocate on cancer drug pricing.
| Title | Journal | Year |
|---|---|---|
| Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia | New England Journal of Medicine | 2016 |
| Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia | New England Journal of Medicine | 2017 |
Shares INO-VATE ALL, INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL, Blinatumomab, MD Anderson Cancer Center.
Shares Blinatumomab, Imatinib, Acute lymphoblastic leukaemia.
Shares INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL, Acute lymphoblastic leukaemia.
Shares Blinatumomab, Imatinib, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares INO-VATE ALL, INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL, Acute lymphoblastic leukaemia.
Shares Blinatumomab, Imatinib, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia.
Shares MD Anderson Cancer Center, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.